The role of HIV-1 DNA as an additional marker of HIV-1 infection

Current HIV Research

Volumn 7, Issue 3, 2009, Pages 255-265

  Beloukas, Apostolos ^a   Paraskevis, Dimitrios ^a   Psichogiou, Mina ^a   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Disease progression; HIV 1 DNA; Prognostic marker; Real time PCR

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA;

ANALYTIC METHOD; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; END POINT POLYMERASE CHAIN REACTION ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEIC ACID ANALYSIS; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PROVIRUS; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PROGNOSIS; PROVIRUSES;

EID: 67649121909     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209788348001     Document Type: Review

References (140)

1. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 2161-7.
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIVinfected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160: 659-65.
3. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-8.
4. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
5. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340: 1614-22.
6. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-7.
7. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300.
8. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339: 1803-9.
9. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195: 1762-4.
10. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy. J Infect Dis 2008; 197: 714-20.
11. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77: 11212-9.
12. Havlir DV, Koelsch KK, Strain MC, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191: 1164-8.
13. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999; 96: 10958-61.
14. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 8869-73.
15. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-8.
16. Chun TW, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115: 3250-5.
17. Hatzakis AE, Touloumi G, Pantazis N, et al. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 2004; 18: 2261-7.
18. Hatzakis A, Touloumi G, Karanicolas R, et al. Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 2000; 355: 599-604.
19. Katzenstein TL, Oliveri RS, Benfield T, Eugen-Olsen J, Nielsen C, Gerstoft J. Cell-associated HIV DNA measured early during infection has prognostic value independent of serum HIV RNA measured concomitantly. Scand J Infect Dis 2002; 34: 529-33.
20. Palmisano L, Giuliano M, Chiarotti F, et al. Modifications of HIV- 1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2008; 48: 68-71.
21. Rouzioux C, Hubert JB, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192: 46-55.
22. Re MC, Vitone F, Bon I, Schiavone P, Gibellini D. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol 2006; 29: 81-8.
23. Re MC, Vitone F, Sighinolfi L, Schiavone P, Ghinelli F, Gibellini D. Different patterns of HIV-1 DNA after therapy discontinuation. BMC Infect Dis 2005; 5: 69.
24. Sarmati L, Parisi SG, Nicastri E, et al. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 2005; 43: 6183-5.
25. Sarmati L, Parisi SG, Nicastri E, et al. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor- sparing regimens. J Med Virol 2007; 79: 880-6.
26. Palmisano L, Giuliano M, Nicastri E, et al. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005; 19: 1843-7.
27. Belmonte L, Bare P, de Bracco MM, Ruibal-Ares BH. Reservoirs of HIV replication after successful combined antiretroviral treatment. Curr Med Chem 2003; 10: 303-12.
28. Avettand-Fenoel V, Mahlaoui N, Chaix ML, et al. Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. AIDS 2007; 21: 776-7.
29. Vitone F, Gibellini D, Schiavone P, Re MC. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J Clin Virol 2005; 33: 194-200.
30. Valentin A, Trivedi H, Lu W, Kostrikis LG, Pavlakis GN. CXCR4 mediates entry and productive infection of syncytia-inducing (X4) HIV-1 strains in primary macrophages. Virology 2000; 269: 294-304.
31. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002; 99: 7015-20.
32. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. Top HIV Med 2006; 14: 827-43.
33. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80: 6441-57.
34. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-93.
35. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
36. Kelly J, Beddall MH, Yu D, Iyer SR, Marsh JW, Wu Y. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 2008; 372: 300-12.
37. Mansharamani M, Graham DR, Monie D, et al. Barrier-toautointegration factor BAF binds p55 Gag and matrix and is a host component of human immunodeficiency virus type 1 virions. J Virol 2003; 77: 13084-92.
38. Chen H, Engelman A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc Natl Acad Sci USA 1998; 95: 15270-4.
39. Farnet CM, Bushman FD. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 1997; 88: 483-92.
40. Lin CW, Engelman A. The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J Virol 2003; 77: 5030-6.
41. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71: 5382-90.
42. Fouchier RA, Malim MH. Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res 1999; 52: 275-99.
43. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993; 90: 6125-9.
44. Karageorgos L, Li P, Burrell C. Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses 1993; 9: 817-23.
45. Robinson HL, Zinkus DM. Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol 1990; 64: 4836-41.
46. Kim SY, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989; 63: 3708-13.
47. Barbosa P, Charneau P, Dumey N, Clavel F. Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res Hum Retroviruses 1994; 10: 53-9.
48. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001; 7: 631-4.
49. Vandegraaff N, Kumar R, Burrell CJ, Li P. Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA. J Virol 2001; 75: 11253-60.
50. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 2002; 8: 673-80.
51. Morlese J, Teo IA, Choi JW, Gazzard B, Shaunak S. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. AIDS 2003; 17: 679-83.
52. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 2000; 6: 76-81.
53. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005; 79: 5203-10.
54. Chavez HH, Tran TA, Dembele B, et al. Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo. J Acquir Immune Defic Syndr 2007; 45: 247-9.
55. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76: 4138-44.
56. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76: 3739-47.
57. Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001; 293: 1503-6.
58. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J 1990; 9: 1551-60.
59. Wu Y, Marsh JW. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003; 77: 10376-82.
60. Wu Y. HIV-1 gene expression: lessons from provirus and nonintegrated DNA. Retrovirology 2004; 1: 13.
61. Montoya JG, Wood R, Katzenstein D, Holodny M, Merigan TC. Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect. J Clin Microbiol 1993; 31: 2692-6.
62. Aoki S, Yarchoan R, Thomas RV, et al. Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2′,3′-dideoxyinosine (ddI). AIDS Res Hum Retroviruses 1990; 6: 1331-9.
63. Bieniasz PD, Ariyoshi K, Bourelly MA, et al. Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individuals. AIDS 1993; 7: 803-6.
64. Gupta P, Ding M, Cottrill M, et al. Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay. J Clin Microbiol 1995; 33: 1670-3.
65. Izopet J, Tamalet C, Pasquier C, et al. Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay. J Med Virol 1998; 54: 54-9.
66. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335: 1091-8.
67. Lin HJ, Haywood M, Hollinger FB. Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA. J Clin Microbiol 1996; 34: 329-33.
68. Mallet F, Hebrard C, Livrozet JM, et al. Quantitation of human immunodeficiency virus type 1 DNA by two PCR procedures coupled with enzyme-linked oligosorbent assay. J Clin Microbiol 1995; 33: 3201-8.
69. Sei S, Kleiner DE, Kopp JB, et al. Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction. J Infect Dis 1994; 170: 325-33.
70. Vesanen M, Stevens CE, Taylor PE, Rubinstein P, Saksela K. Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J Virol 1996; 70: 9035-40.
71. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin LH. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 358-64.
72. Furtado MR, Kingsley LA, Wolinsky SM. Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol 1995; 69: 2092-2100.
73. Menzo S, Bagnarelli P, Giacca M, Manzin A, Varaldo PE, Clementi M. Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol 1992; 30: 1752-7.
74. Frenkel LM, Wang Y, Learn GH, et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 2003; 77: 5721-30.
75. Nygren M, Ronaghi M, Nyren P, Albert J, Lundeberg J. Quantification of HIV-1 using multiple quantitative polymerase chain reaction standards and bioluminometric detection. Anal Biochem 2001; 288: 28-38.
76. Teo I, Veryard C, Barnes H, et al. Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol 1997; 71: 2928-33.
77. Vandegraaff N, Kumar R, Hocking H, et al. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother 2001; 45: 2510-6.
78. Debiaggi M, Zara F, Pistorio A, et al. Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy. Int J Infect Dis 2000; 4: 187-93.
79. McDermott JL, Giri AA, Martini I, et al. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol 1999; 37: 2361-5.
80. Comandini UV, Sonnerborg A, Vahlne A, Yun Z. Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR. J Virol Methods 1997; 69: 171-80.
81. Comar M, Simonelli C, Zanussi S, et al. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest 1997; 100: 893-903.
82. Holodniy M, Katzenstein DA, Sengupta S, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991; 163: 862-6.
83. Gupta P, Kingsley L, Armstrong J, Ding M, Cottrill M, Rinaldo C. Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology 1993; 196: 586-95.
84. Garbuglia AR, Salvi R, Di Caro A, et al. Peripheral lymphocytes of clinically non-progressor patients harbor inactive and uninducible HIV proviruses. J Med Virol 1995; 46: 116-21.
85. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 1994; 205: 470-8.
86. Christopherson C, Kidane Y, Conway B, Krowka J, Sheppard H, Kwok S. PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J Clin Microbiol 2000; 38: 630-4.
87. Lillo FB, Grasso MA, Lodini S, Bellotti MG, Colucci G. Few modifications of the Cobas Amplicor HIV Monitor 1.5 test allow reliable quantitation of HIV-1 proviral load in peripheral blood mononuclear cells. J Virol Methods 2004; 120: 201-5.
88. Jennings C, Danilovic A, Scianna S, Brambilla DJ, Bremer JW. Stability of human immunodeficiency virus type 1 proviral DNA in whole-blood samples. J Clin Microbiol 2005; 43: 4249-50.
89. Beloukas A, Paraskevis D, Haida C, Sypsa V, Hatzakis A. Development and Assessment of a multiplex Real-Time PCR Assay for the Quantification of HIV-1 DNA (RTW-HM). J Clin Microbiol 2009; (submitted).
90. Eriksson LE, Leitner T, Wahren B, Bostroin AC, Falk KI. A multiplex real-time PCR for quantification of HIV-1 DNA and the human albumin gene in CD4+ cells. Apmis 2003; 111: 625-33.
91. Gibellini D, Monari P, Sassi M, Re MC. A rapid hemi-nested PCR for HTLV-I detection. J Clin Virol 2003; 28: 341-3.
92. Kostrikis LG, Touloumi G, Karanicolas R, et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76: 10099-108.
93. Sharova N, Swingler C, Sharkey M, Stevenson M. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J 2005; 24: 2481-9.
94. Yun Z, Fredriksson E, Sonnerborg A. Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay. J Clin Microbiol 2002; 40: 3883-4.
95. Zhao Y, Yu M, Miller JW, et al. Quantification of human immunodeficiency virus type 1 proviral DNA by using TaqMan technology. J Clin Microbiol 2002; 40: 675-8.
96. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretra-viral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999; 180: 320-9.
97. Kabamba-Mukadi B, Henrivaux P, Ruelle J, Delferriere N, Bodeus M, Goubau P. Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCR. BMC Infect Dis 2005; 5: 15.
98. Casabianca A, Gori C, Orlandi C, Forbici F, Federico Perno C, Magnani M. Fast and sensitive quantitative detection of HIV DNA in whole blood leucocytes by SYBR green I real-time PCR assay. Mol Cell Probes 2007; 21: 368-78.
99. Desire N, Dehee A, Schneider V, et al. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol 2001; 39: 1303-10.
100. Goedert JJ, O'Brien T?, Hatzakis A, Kostrikis LG. T cell receptor excision circles and HIV-1 2-LTR episomal DNA to predict AIDS in patients not receiving effective therapy. AIDS 2001; 15: 2245-50.
101. Garbuglia M, Bianchi R, Verzini M, Giambanco I, Donato R. Annexin II2-p11(2) (calpactin I) stimulates the assembly of GFAP in a calcium- and pH-dependent manner. Biochem Biophys Res Commun 1995; 208: 901-9.
102. Zazzi K Romano L, Catucci M, et al. Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. J Med Virol 1997; 52: 20-5.
103. Teo IA, Morlese J, Choi JW, Shaunak S. Reliable and reproducible LightCycler qPCR for HIV-1 DNA 2-LTR circles. J Immunol Methods 2002; 270: 109-18.
104. Moroney SM, Heller LC, Widen RH. Evaluation of two TaqMan PCR assays for the detection of HIV-1 proviral DNA in blood samples. J Microbiol Methods 2006; 65: 350-3.
105. Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18: 45-9.
106. Gibellini D, Vitone F, Schiavone P, Ponti C, La Placa M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J Clin Virol 2004; 29: 282-9.
107. Zanchetta M, Walker S, Burighel N, et al. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J Infect Dis 2006; 193: 1718-27.
108. Carr JM, Cheney KM, Coolen C, et al. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol 2007; 45: 1288-97.
109. Gibellini D, Vitone F, Gori E, La Placa M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. J Virol Methods 2004; 115: 183-9.
110. Katzenstein TL, Ullum H, Rogd BT, et al. Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med 2003; 4: 53-61.
111. Ngo-Giang-Huong N, Deveau C, Da Silva I, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15: 665-73.
112. McDermott JL, Martini I, Ferrari D, et al. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J Clin Microbiol 2005; 43: 5272-4.
113. Brussel A, Delelis O, Sonigo P. Alu-LTR real-time nested PCR assay for quantifying integrated HIV-1 DNA. Methods Mol Biol 2005; 304: 139-54.
114. Kumar R, Vandegraaff N, Mundy L, Burrell CJ, Li P. Evaluation of PCR-based methods for the quantitation of integrated HIV-1 DNA. J Virol Methods 2002; 105: 233-46.
115. Yamamoto N, Tanaka C, Wu Y, et al. Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-time polymerase chain reaction. Virus Genes 2006; 32: 105-13.
116. Fischer M, Trkola A, Joos B, et al. Shifts in cell-associated HIV-1 RNA but not in episomal HlV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antivir Ther 2003; 8: 97-104.
117. Clark AG, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J Acquir Immune Defic Syndr 1992; 5: 52-9.
118. Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007; 45: 381-90.
119. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Khiri H, Halfon P. Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. HIV Med 2001; 2: 189-94.
120. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 2003; 188: 1426-32.
121. Torti C, Quiros-Roldan ME, Cologni G, et al. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naive to antiretrovirals. Curr HIV Res 2008; 6: 43-8.
122. Andreoni M, Parisi SG, Sarmati L, et al. Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and >500 × 10(6)/1 CD4 cells treated with highly active antiretroviral therapy. AIDS 2000; 14: 23-9.
123. Burgard M, Izopet J, Dunion B, et al. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. AIDS Res Hum Retroviruses 2000; 16: 1939-47.
124. Gibellini D, Borderi M, De Crignis E, et al. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naive and HAART-treated individuals. J Infect 2008; 56: 219-25.
125. Morand-Joubert L, Marcellin F, Launay O, et al. Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of anti-retroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081). J Acquir Immune Defic Syndr 2005; 38: 268-76.
126. Tierney C, Lathey JL, Christopherson C, et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003; 187: 144-8.
127. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42: 709-15.
128. Opravil M, Ledergerber B, Furrer H, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 10(6)/l. AIDS 2002; 16: 1371-81.
129. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-77.
130. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33.
131. Gulick RM. Current antiretroviral therapy: an overview. Qual Life Res 1997; 6: 471-4.
132. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
133. Yerly S, Kaiser L, Perneger TV, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000; 14: 243-9.
134. Pomerantz RJ. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Biomed Pharmacother 2001; 55: 7-15.
135. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 1627-32.
136. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 2001; 286: 171-9.
137. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 4531-6.
138. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20: 1727-36.
139. Chun TW, Justement JS, Pandya P, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185: 1672-6.
140. Yerly S, Gunthard HF, Fagard C, et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. Aids 2004; 18: 1951-3.